Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab.

Abstract

Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metastasis developed and afatinib effectively relieved dysphonia associated with nerve paralysis.

• Authors: Yinghua Jin, Qiuying Jiang, Tao Xin
• Journal: Thoracic cancer (Thorac Cancer) Vol. 9 Issue 1 Pg. 164-166 (01 2018) ISSN: 1759-7714 [Electronic] Singapore
• PMID: 29027754 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Chemical References

• Antibodies, Monoclonal
• Quinazolines
• Nivolumab
• Afatinib

Topics

• Afatinib
• Aged
• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Carcinoma, Squamous Cell (drug therapy, pathology)
• Disease Progression
• Humans
• Lung Neoplasms (drug therapy, pathology)
• Male
• Nivolumab
• Quinazolines (pharmacology, therapeutic use)